Welcome to LiVDerm
Where the Constellations of Medical Dermatology and Aesthetics Collide
Led by world-renowned experts in the field, LiVDerm is a comprehensive dermatologic hub where medical professionals educate, collaborate, and engage.
LiVDerm’s mission is to boldly advance higher standards of dermatology care through live and virtual educational offerings, resources for providers, students and patients, and much more.
As a leading source for the latest therapies, technologies, procedures, and practice guidelines in medical and aesthetic dermatology, LiVDerm empowers providers to manage dermatologic conditions with confident authority. With a multipronged focus on the myriad specialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.
Upcoming Live Events
Complimentary Continuing Education
Chronic Urticaria
Interactive Monograph
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria Beyond Skin Deep
Atopic Dermatitis
Enduring Webcast
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis
Seborrheic Dermatitis
Enduring Webcast
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
LivDerm Articles
FDA Findings of Benzene Contamination in Benzoyl Peroxide Acne Products
During a recent investigation, the U.S. Food and Drug Administration (FDA) conducted testing on 95 acne products containing benzoyl peroxide to assess potential benzene contamination.…
L'Oréal Recalls Acne Treatment Due to Benzene Concerns
L’Oréal has voluntarily recalled all lots of its acne treatment, Effaclar Duo, in the U.S. due to concerns that the product may be contaminated with…
Preventing Post-Inflammatory Hyperpigmentation in Skin of Color: A Systematic Review
Research has shown that individuals with darker Fitzpatrick skin types (III-VI) face a higher risk of developing post-inflammatory hyperpigmentation (PIH). According to studies, this increased…
FDA Clears Investigational New Drug Application for Zabalafin Hydrogel for Atopic Dermatitis
Alphyn has announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin Hydrogel, a groundbreaking treatment…
Breakthrough in Bullous Pemphigoid Treatment: FDA Fast-Tracks Dupixent sBLA
A potential new treatment for bullous pemphigoid (BP) is on the horizon as the U.S. Food and Drug Administration (FDA) grants priority review to Dupixent’s…
Galderma Trial Reveals Promising Results for Restoring Facial Volume After Weight Loss with Combination Treatment
Galderma recently announced the results of its clinical trial exploring the benefits of combining Restylane® Lyft™ or Contour™ with Sculptra® in patients experiencing facial volume…
New Treatment Shows Promise for Adolescent CHE
DELTA TEEN is a phase 3 clinical trial by LEO Pharma that evaluated Anzupgo® (delgocitinib) 20mg/g cream for adolescents with moderate-to-severe chronic hand eczema (CHE).…
Baricitinib and Narrowband UV-B: Promising Results from a Phase 2 Study on Severe Vitiligo
During a recent phase 2 study, researchers revealed that a combination of baricitinib and narrowband UV-B therapy significantly improved both disease activity and quality of…
FDA Clears Fesarius Therapeutics’ DermiSphere hDRT for Wound Care
Fesarius Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its DermiSphere Hydrogel Dermal Regeneration Template (DermiSphere…
A Growing Trend: Survey Explores Cosmetic Procedures in Pediatric Dermatology
Although cosmetic treatments have traditionally been geared more towards the adult population, current data reveals a growing trend in cosmetic procedures among pediatric patients. This…
Axolotl's Potential in Skin Regeneration: A Breakthrough for Medicine
Research conducted over the years has led to the discovery of the axolotl salamanders (Ambystoma mexicanum) and their remarkable regenerative abilities. These findings offer promising…
Bristol Myers Squibb Announces Positive Topline Results in Phase 3 Sotyktu Trials
In a recent press release, Bristol Myers Squibb announced the positive results of their pivotal Phase 3 trials (POETYK PsA-1 and POETYK PsA-2) evaluating the…
The Evolving Role of AI in Medical Research
A recent Medscape report revealed that 24% of respondents use AI tools to analyze medical literature and data. While these AI tools can help organize…
FDA Approves Vtama for Atopic Dermatitis for Patients Two Years and Above
Organon has announced the recent approval of Vtama ® (tapinarof) cream 1% for atopic dermatitis (AD) in adults and children aged 2 years and older. Vtama,…
Study Finds Ultraprocessed Foods Linked to Active Psoriasis
Diet, which plays a critical role in reducing inflammation and improving quality of life, has emerged as a significant factor in managing inflammatory diseases. Concerns,…
Study Highlights Safety and Efficacy of Monopolar Radiofrequency and HIFES in Patients Receiving Botulinum Toxin
A recent study published in the Journal of Drugs in Dermatology evaluated the safety and efficacy of a novel device combining monopolar radiofrequency (RF) and…
FDA Approves BIMZELX for Moderate-to-Severe Hidradenitis Suppurativa
UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in…
New Protection and Repair Skincare Regimen Improves Photoaging
A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen,…
Study Evaluates Relationship Between Hidradenitis Suppurativa and Precocious Puberty
A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from…
FDA Grants Rare Pediatric Disease Designation for BPGbio’s BPM31510T for EB
The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news…
LivDerm Podcasts
IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis
Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?
Exploring the Latest Updates in the Epidermolysis Bullosa Treatment Landscape
Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management
Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis
Skirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term Control
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?
Skirting Steroids in Atopic Dermatitis: Dangers and Side Effects of Steroid Exposure in Treatment of AD
Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy
The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence
Targeted Intervention for Hidradenitis Suppurativa: Defining Window of Opportunity for Moderate-to-Severe Patients
Psoriasis in Skin of Color Unplugged: Patient and Disease Advocacy
Psoriasis in Skin of Color Unplugged: Advancing Diversity and Inclusion in Clinical Trials
Psoriasis in Skin of Color Unplugged: Gaps in Diagnosis and Dermatologist Training
Psoriasis in Skin of Color Unplugged: Disparities and Access to Care
The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors
